



**Press Release**

**For immediate release**

**CAPLIN STERILES GETS USFDA APPROVAL FOR SUMATRIPTAN INJECTION**

**Chennai, July 14, 2021: Caplin Point Laboratories Limited** (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 6 mg/0.5 mL (12 mg/mL) Single dose Vials, a generic therapeutic equivalent version of (RLD), IMITREX Injection, of GlaxoSmithKline, USA.

Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache. According to IQVIA™ (IMS Health), Sumatriptan Injection had US sales data of approximately \$5 million for the 12-month period ending March 2021, for Vial presentation.

**ABOUT CAPLIN STERILES LTD**

Caplin Steriles Ltd, a Subsidiary of Caplin Point Laboratories Limited, is a niche sterile product manufacturing company that is approved by US FDA and EU-GMP. Caplin Steriles Limited, has developed and filed 20 ANDAs in USA on its own and with partners, with 16 approvals so far. The Company is also working on a portfolio of 35 simple and complex Injectable and Ophthalmic products, that it intends to file over the next 4 years.

**ABOUT CAPLIN POINT LABORATORIES LIMITED**

Caplin Point Laboratories Limited is a fast-growing pharmaceutical Company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company's Subsidiary Caplin Steriles Limited caters to the Regulated Markets for Injectable and Ophthalmic products.



Caplin Point Laboratories Limited has been selected on Forbes Asia's "200 Best Under a Billion" list for three consecutive years (2014, 2015 & 2016), and was also awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

**Cautionary Statement:**

*This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

For details, please contact:

<p><b>Investor Relations at Caplin</b> Mr. Dinesh R G (Company Secretary) Tel: +91 44 24968000 <a href="mailto:investor@caplinpoint.net">investor@caplinpoint.net</a></p> <p>Mr. Rahul Thakur Christensen Advisory <a href="mailto:rthakur@christensenir.com">rthakur@christensenir.com</a></p>	<p><b>Registered Office</b> 3<sup>rd</sup> Floor, Ashvich Towers, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096, Tamil Nadu, INDIA. Tel : +91 44 2496 8000 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 Website: <a href="http://www.caplinpoint.net">www.caplinpoint.net</a></p>
---	---